Indo Us Bio-Tech Ltd (INDOUS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Indo Us Bio-Tech Ltd on NSE and BSE, with an AI summary of each filing.
Indo Us Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Financial Result · 30 Oct 2026, 9:52 pm
Unaudited Financial Results for the quarter ended on 30-09-2026
Financial Result · 30 Oct 2026, 9:48 pm
Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting ....
Outcome · 30 Oct 2026, 9:42 pm
Indo Us Bio-Tech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 1,505 (-51.2% YoY | -54.4% QoQ) ■ EBITDA: -260 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -17.3 (Profit to Loss YoY | Profit to Loss QoQ) ■ PAT: -367 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -1.83 (Profit to Loss YoY | Profit to Loss QoQ)
INDO US BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 30 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 30 Oct 2026, 5:30 am
INDO US BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 30 Oct 2026, 5:30 am
Indo Us Bio-Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve and take on record the Un-Audited ....
Intimation · 30 Oct 2026, 5:30 am
Indo Us Bio-Tech Schedules Board Meeting to Approve Q2 FY27 Financial Results Indo Us Bio-Tech Limited has scheduled a meeting of its Board of Directors on 30th Oct'26. The board will convene primarily to consider, approve, and take on record the un-audited standalone financial results of the company for the second quarter and half year ended 30th Sep'26, alongside other general corporate matters.
Directors cum promoters and other promoter visit china
Others (Uncategorized) · 23 Oct 2026, 9:44 pm
Indo Us Bio-Tech Promoters Invited to Attend 140th Canton Fair in China Indo Us Bio-Tech Limited disclosed that Managing Director cum Promoter Jagdish Ajudia, Executive Director cum Promoter Priyanka Samarth Patel, and Promoter Samarth Patel have received invitations to attend the 140th China Import and Export Fair (Canton Fair) in Guangzhou, China. The multi-phase event showcases diverse industrial, agricultural machinery, chemical, and consumer sectors. The company reported this overseas travel invitation under SEBI Regulation 30 disclosures on 23rd Oct'26.
Voting Results and Scrutinizer''s Report for passing resolutions through remote e voting in 22nd AGM of the Company
Annual General Meeting · 02 Oct 2026, 8:35 pm
Pursuant to regulation 30 of SEBI LODR Regulations, we here by enclose a gist of proceedings of 22nd AGM held on Wednesday 30th September, 2026. Request you to take the same on the record ....
Annual General Meeting · 01 Oct 2026, 12:09 am
Annual Report 2025-26
Others (Uncategorized) · 05 Sept 2026, 9:03 pm
Book closure period from 23rd September, 2026 to 30th September, 2026 (Both inclusive days) for the purpose of 22nd AGM of the company to be held on 30th Sep, 2026.
Annual General Meeting · 05 Sept 2026, 8:50 pm
AGM to be held on Wednesday 30-09-2026 at 02:30 pm through VC/OCAM.
Annual General Meeting · 05 Sept 2026, 8:40 pm
Indo Us Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026.
Outcome · 05 Sept 2026, 8:31 pm
Indo US Bio-Tech Board Approves AGM, Book Closure, and Auditor Appointment Indo US Bio-Tech Limited's board approved convening the 22nd Annual General Meeting (AGM) on 30th Sep'26 via video conferencing. The register of members and share transfer books will remain closed from 23rd Sep'26 to 30th Sep'26 for AGM purposes. The voting cut-off date is set for 23rd Sep'26, with remote e-voting running from 27th Sep'26 to 29th Sep'26. Additionally, the board recommended appointing M/s. Bhagat & Associates as statutory auditors for five consecutive years (from the 22nd AGM to the 27th AGM), subject to shareholder approval.
The Board met today, discussed and resolved the agendas mentioned in attachment & attached Annexure A Book Closure Date (both days inclusive).
Others (Uncategorized) · 05 Sept 2026, 8:27 pm
Indo US Bio-Tech Board Approves AGM Dates, Auditor Appointment, and Book Closure Indo US Bio-Tech Limited scheduled its 22nd AGM for 30th Sep'26 via video conferencing. The cut-off date for e-voting eligibility is 23rd Sep'26, with the remote e-voting window running from 27th Sep'26 to 29th Sep'26. Register of members and share transfer books will remain closed from 23rd Sep'26 to 30th Sep'26. Additionally, the Board recommended appointing M/s. Bhagat & Associates as Statutory Auditors for a five-year term spanning the 22nd to 27th AGM, subject to shareholder approval.
Financial Results for the quarter ended on 30-06-2026
Financial Result · 12 Aug 2026, 9:04 pm
Indo US Bio-Tech Q1FY27 Results: PAT Declines YoY Amid Higher Revenue Indo US Bio-Tech reported standalone results for Q1FY27 (quarter ended 30-Jun'26), showing a 35.4% YoY decline in Net Profit to ₹303.74 lakhs despite a 7.2% YoY rise in Revenue from Operations to ₹3,298.68 lakhs. Total expenses increased 15.7% YoY to ₹3,003.35 lakhs. Profit Before Tax (PBT) fell 36.2% YoY to ₹307.70 lakhs. Sequentially, PAT grew 54.1% QoQ from ₹197.17 lakhs. Basic EPS for the quarter stood at ₹1.51, down from ₹2.35 in the prior year's quarter.
Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting ....
Outcome · 12 Aug 2026, 8:53 pm
Indo Us Bio-Tech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 3,299 (+7.2% YoY | +26.8% QoQ) ■ EBITDA: 396 (-27.6% YoY | +22.7% QoQ) ■ EBITDA Margin (%): 12.0 (-577 bps YoY | -40 bps QoQ) ■ PAT: 304 (-35.4% YoY | +54.0% QoQ) ■ EPS (INR): 1.51 (-35.7% YoY | +54.1% QoQ)
Indo Us Bio-Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve (a) The Unaudited Financial ....
Intimation · 12 Aug 2026, 5:30 am
Indo Us Bio-Tech Sets Board Meeting for Q1FY27 Results Indo Us Bio-Tech Limited scheduled a Board of Directors meeting on 12th Aug'26 to consider and approve the unaudited financial results for the quarter ended 30th Jun'26. In connection with this, the trading window for insiders, which closed on 1st Jul'26, will remain closed until 48 hours after the results are announced. The agenda also includes other corporate matters.
Committee Composition approved in the Outcome of Board Meeting dated 10th July, 2026 shall be read as effective from 21st April, 2026, being the effective date of the Appointment and resignation ....
Outcome · 15 Jul 2026, 9:54 pm
Indo US Bio-Tech Revises Board Committee Composition Indo US Bio-Tech has reconstituted its board committees with an effective date of 21 Apr'26, following director appointments and resignations. The Audit Committee will be chaired by Ritaben Nileshbhai Kikani. The Nomination and Remuneration Committee will be chaired by Shilpa Chetanbhai Thumar. The Stakeholders Relationship Committee will be chaired by Ritaben Nileshbhai Kikani. This revision corrects the effective date previously reported in the board meeting outcome of 10 Jul'26. All other disclosures from that meeting remain unchanged.
Revised announcement submit.
Change in Auditor · 15 Jul 2026, 9:24 pm
Indo Us Bio-Tech Appoints New Statutory Auditor Post Resignation Indo Us Bio-Tech announced M/s. Gautam N Associates resigned as Statutory Auditor effective 15-Jun'26, citing the company's administrative and operational restructuring. The firm confirmed no other material reasons for the departure. Subsequently, the Board approved the appointment of M/s. Bhagat & Associates (FRN: 101100W) as the new Statutory Auditor, effective from the same date. The appointment is subject to shareholder approval at the next General Meeting. This change aims to optimize logistical efficiencies and facilitate closer local coordination with an Ahmedabad-based auditor.
Pursuant to the resignation of Mrs. Nehaben Patel (DIN: 09263180) from the office of Non-Executive Independent Director of the Company, the Board of Directors, at its meeting held on 21st ....
Others (Uncategorized) · 10 Jul 2026, 9:16 pm
Indo Us Bio-Tech Announces Board Committee Reconstitution Indo Us Bio-Tech reconstituted its board committees effective 10th Jul'26, following the resignation of Non-Executive Independent Director Nehaben Patel and the appointment of Hemanshi Darsh Soni. Ritaben Nileshbhai Kikani now chairs the Audit and Stakeholders Relationship Committees. Shilpa Chetanbhai Thumar has been appointed Chairperson of the Nomination and Remuneration Committee. These changes were approved in a board meeting held on 10th Jul'26 to maintain regulatory compliance. Hemanshi Darsh Soni joins all three committees as a member.
Regularization of appointment of Mrs. Hemanshi Darsh Soni (DIN: 11659183) as an Non Executive Independent Director of the Company, appointment of M/s. Bhagat & Associates, Chartered Accountants ....
Others (Uncategorized) · 04 Jul 2026, 12:14 am
Indo US Bio-Tech Approves Director and Auditor Appointments via Postal Ballot Indo US Bio-Tech's board, at its 03-Jul'26 meeting, approved two key proposals subject to shareholder approval via postal ballot. The first is the regularization of Mrs. Hemanshi Darsh Soni as a Non-Executive Independent Director for a five-year term. The second is the appointment of M/s. Bhagat & Associates, Chartered Accountants (FRN: 101100W), as Statutory Auditors for five years, effective from 16-Jun'26. The cut-off date for e-voting eligibility is 26-Jun'26, with the voting period ending 03-Aug'26.
Resignation and Appointment of Statutory Auditor
Change in Auditor · 17 Jun 2026, 10:12 pm
Indo Us Bio-Tech Appoints New Statutory Auditor Following Resignation Indo Us Bio-Tech announced that Gautam N Associates resigned as Statutory Auditor effective 15-Jun'26, citing "administrative and operational restructuring" of the audit assignments. The auditor confirmed no other material reasons for the resignation. Subsequently, on 16-Jun'26, the Board of Directors approved the appointment of Bhagat & Associates as the new Statutory Auditor. Their term begins immediately and is subject to shareholder approval at the next general meeting. This change aims to optimize logistical efficiencies and facilitate closer local coordination.
Appointment and Resignation of Statutory Auditors and Internal Auditors.
Change in Auditor · 16 Jun 2026, 9:41 pm
Indo Us Bio Tech Appoints New Statutory and Internal Auditors Indo Us Bio Tech announced key auditor changes on 16-Jun'26. Gautam N Associates resigned as Statutory Auditor, citing administrative restructuring, effective 15-Jun'26. The board appointed Bhagat & Associates as the new Statutory Auditor. Concurrently, Internal Auditor Raj Shah & Co. resigned, effective 15-Jun'26, and was replaced by J. M. Raval & Co. The appointments are subject to shareholder approval where required.
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circulars issued thereunder, we wish to ....
Others (Uncategorized) · 16 Jun 2026, 9:34 pm
Indo US Bio-Tech Appoints New Statutory and Internal Auditors Indo US Bio-Tech announced key changes to its auditors. The board has appointed M/s. Bhagat & Associates as the new Statutory Auditor, effective 16th Jun'26, following the resignation of M/s. Gautam N Associates on 15th Jun'26. The outgoing auditor cited administrative and operational restructuring as the reason for resignation. Additionally, M/s. J. M. Raval & Co. was appointed as the new Internal Auditor from 16th Jun'26, replacing M/s. Raj Shah & Co., who resigned effective 15th Jun'26.